BioSpace News Archive

Kintor Pharmaceutical Limited today announced its 2022 interim results and released an update on its recent business highlights.

Urologists at Hackensack University Medical Center have become the first in northern New Jersey to offer an innovative treatment for benign prostatic hyperplasia that uses a high-intensity waterjet to destroy excess prostate tissue that causes uncomfortable urinary symptoms for many older men.

Wenzel Spine, Inc., today announced the launch of the S-LIF Procedure for Stand-alone Lumbar Interbody Fusion using the VariLift®-LX device, the only stand-alone expandable posterior lumbar interbody fusion device that is FDA-cleared for 1 or 2 level fusion.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes™ trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress.

Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.

Each year, more than 48 million cases of sepsis are diagnosed and account for 11 million deaths annually.

The global antibody fragments market was estimated at USD 7.2 billion in 2021 and it is expected to surpass around USD 11.89 billion by 2030, poised to grow at a CAGR of 5.73% from 2022 to 2030.

The global artificial intelligence in the precision medicine market is expected to witness growth from 2022 to 2030 owing to rising advancements in the healthcare sector.

According to Vision Research Report, the global cell-free protein expression market was valued at USD 229.82 million in 2021 and it is predicted to surpass around USD 475.33 million by 2030 with a CAGR of 8.41% from 2022 to 2030.

The global stomach cancer treatment market was estimated at USD 3.94 billion in 2021 and is expected to hit around USD 11.5 billion by 2030, growing at a CAGR of 12.64% from 2022 to 2030.